


Abstract summaries for ACR

Discover some of the scientific data we are presenting this year at the American College of Rheumatology (ACR) Virtual Meeting 2020. Please note that abstract summaries only contain information from the full scientific abstract and selected supporting references. These abstracts have been adapted into plain language summaries to help translate complex data into digestible information. The results of these studies may not reflect those of other studies. Summaries are not intended to provide medical advice nor intended for promotional use.



The image shows a preview of a 'Plain Language Media Summary' document. The document header includes the Novartis logo and the title 'Secukinumab effect on ankylosing spondylitis'. The main text area contains the following information:

- Full abstract title:** Subcutaneous secukinumab for the treatment of ankylosing spondylitis: End-of-study results
- Abstract authors:** Marzo-Ortega H, Mikolajczyk S, et al.
- Date:** November 2020
- Please note that this summary only contains selected supporting references. The rest of the summary is not intended to provide medical advice.**

Below the text is a diagram illustrating the relationship between different types of spondyloarthritis. At the top is 'axSpA'. A line connects it to two categories below: 'nr-axSpA' (non-radiographic axial spondyloarthritis) on the left and 'AS' (ankylosing spondylitis) on the right. Each category is accompanied by a blue line-art icon of a human torso showing the spine and pelvis. The 'nr-axSpA' icon shows a normal spine, while the 'AS' icon shows a spine with inflammation (indicated by red wavy lines) and a fused pelvis.

Secukinumab effect on the severity of ankylosing spondylitis after 5 years

A simplified overview of the abstract presented November 6, 2020.

[Open summary \(PDF 0.1 MB\)](#)


Plain Language Media Summary

Secukinumab as a treatment for psoriatic arthritis predominantly affecting the back and neck

Full abstract title: Secukinumab promotes improved outcomes in patients with psoriatic arthritis predominantly affecting the back and neck (axial joints) in the MAXIMISE trial

Abstract authors: Baraliakos X, Gossec L
Date: November 2020

Please note that this summary only contains the key findings and selected supporting references. The full abstract is available on the European Society for Clinical Investigation website. This summary is not intended to provide medical advice or to replace the advice of a healthcare professional.




- pain in the joints and back
- fatigue
- stiffness in the morning
- impaired physical function affecting work and other activities
- problems with self-care
- feelings of anxiety/depression

Secukinumab as a treatment for psoriatic arthritis predominantly affecting the joints of the back and neck (axial joints)

A simplified overview of the abstract presented November 6, 2020.

[Open summary \(PDF 0.1 MB\)](#)



Using sensitive ultrasound imaging to understand speed of secukinumab response in psoriatic arthritis

A simplified overview of the abstract presented November 8, 2020.

[Open summary \(PDF 0.1 MB\)](#)

Plain Language Media Summary

Using machine learning to predict likelihood of achieving relief from psoriatic arthritis

Full abstract title: Machine learning to predict likelihood of achieving relief from psoriatic arthritis

Abstract authors: Mease PJ, van der Horst-Poppe M, et al.

Date: November 2020

Please note that this summary only covers selected supporting references. The full summary is not intended to provide medical advice.

Machine learning was used to look back at data from two clinical trials: **FUTURE 1 and FUTURE 5**

1,554 patients* with PsA

<p>STEP 1</p> <p>Assessed how many patients had joint damage on an X-ray at the start and whether there was a relationship between this damage and how much joint swelling and tenderness patients were experiencing</p>	<p>STEP 2</p> <p>The effect of secukinumab treatment on these symptoms was then studied</p>	<p>STEP 3</p> <p>Machine learning looked for a relationship between patients' response to secukinumab treatment and the amount of joint damage at the start of the study</p>
---	--	---

*Patients receiving secukinumab 75 mg, 150 mg or 300 mg were included in this analysis

Using machine learning to predict likelihood of achieving relief from psoriatic arthritis

A simplified overview of the abstract presented November 9, 2020.

[Open summary \(PDF 0.1 MB\)](#)

Source URL: <https://prod1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-acr>

List of links present in page

- <https://prod1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-acr>
- https://prod1.novartis.com/sites/novartis_com/files/secukinumab-effect-on-severity-of-ankylosing-spondylitis.pdf
- https://prod1.novartis.com/sites/novartis_com/files/secukinumab-treatment-for-psoriatic-arthritis-affecting-joints-of-back-neck.pdf
- https://prod1.novartis.com/sites/novartis_com/files/using-sensitive-ultrasound-imaging-understand-speed-of-secukinumab-response-psoriatic-arthritis.pdf
- https://prod1.novartis.com/sites/novartis_com/files/machine-learning-to-predict-likelihood-of-achievingrelief-from-psoriatic-arthritis.pdf